 |
 |
 |
 |
 |
Treatment Name: |
 |
Phase I Trial of Aflibercept (VEGF Trap)with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Malignant Gliomas |
 |
 |
 |
 |
Phase: |
 |
Phase 1/2 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1815 NABTC 07-01 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
60: Requires occasional assistance but is able to care for most of own needs |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Sometimes Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
10/27/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
VEGF Trap is a specific antagonist that binds and inactivates circulating VEGF in the blood stream and in the extravascular space. Treatment with VEGF Trap is well tolerated and resulted in evaluable response in a significant number of patients when used as a single agent, and constitutes the rationale for combination with temozolomide and radiation therapy following debulking surgery. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy |
 |
 |
 |
 |
Contact: |
 |
Clinical Trials Office - Dana-Farber/Harvard Cancer Center Dana-Farber/Harvard Cancer Center Dana Farber Cancer Institute
Boston, MA 02115 USA Phone: 617-582-8480 Fax: E-mail: Website: |
 |
 |